Aim, principle, apparatus required, materials required, category, procedure, storage , formulation table ,label and report for create nanoemulsion for a particular drug accessing their stability, particle size and drug release characteristics

Aim

To formulate a nanoemulsion for a selected drug (e.g., celecoxib, repaglinide, pterostilbene, amlodipine, fluconazole, curcumin, or cefuroxime axetil) and rigorously evaluate its stability, particle size, and in vitro drug release characteristics for enhanced delivery and bioavailability.

Principle

Nanoemulsions are submicron-sized (typically 20–200 nm) colloidal dispersions of two immiscible liquids, stabilized by a surfactant/co-surfactant system. Their small droplet size increases surface area, improving drug solubilization, dissolution, chemical stability, and bioavailability of hydrophobic drugs. Formulation can be achieved via high-energy (e.g., high-pressure homogenization, ultrasonication) or low-energy (e.g., spontaneous emulsification, phase inversion) techniques. Physicochemical and in vitro characterization ensures suitability for pharmaceutical application[1][2][3][4][5][6][7][8].

Apparatus Required

• Magnetic stirrer with hot plate – for uniform mixing
• High-pressure homogenizer or Ultrasonicator – for nano-size droplet formation
• Vortex mixer – homogenizing small batches
• Centrifuge – for thermodynamic stability evaluation
• Particle size analyzer (e.g., DLS) – for globule size, PDI, and zeta potential measurement
• pH meter – sample pH check
• Viscometer – for viscosity measurement
• UV-Visible spectrophotometer/HPLC – quantification of drug release and content
• Franz diffusion cell or dialysis setup – in vitro drug release/permeation studies
• Refrigerator – storage and stability tests

Materials Required

• Drug: e.g., celecoxib, repaglinide, pterostilbene, etc.
• Oil phase: Selection is drug-dependent; choices include oleic acid, Labrafac, triacetin, sefsol-218, capmul MCM, almond oil, light paraffin, etc.[2][3][4][5][7][8][9][10]
• Surfactant: Tween 80, Tween 20, Cremophor EL, Pluronic F127, etc.[4][5][6][7][8][9][10]
• Co-surfactant: Ethanol, transcutol, PEG 400, Soya lecithin, etc.[3][4][5][7][8]
• Aqueous phase: Double distilled water or phosphate buffer
• pH adjusters: NaOH, HCl
• Dialysis membrane: For in vitro release studies
• Analytical grade solvents/chemicals: As per the quantification method

Category

Pharmaceutical Nanotechnology / Novel Drug Delivery Systems (NDDS) / Nanoemulsion Formulation

Procedure

1. Screening & Solubility Studies:

   • Solubility of the drug in various oils, surfactants, and co-surfactants must be determined. The components with highest drug affinity and emulsification capability are selected[2][3][5][7][8].

2. Pseudoternary Phase Diagram Construction (recommended):

   • Prepare mixtures of oil, surfactant, and co-surfactant at varied ratios (e.g., 1:1, 2:1 Smix) and titrate with aqueous phase.
   • Identify the nanoemulsion region (transparent, low viscosity) visually or via laser droplet size analysis[2][3][4][5][7][8].
   • Choose component ratios that offer the widest and most robust nanoemulsion region.

3. Nanoemulsion Preparation:

   • Accurately weigh the drug and dissolve it in the selected oil phase by stirring.
   • Prepare Smix (surfactant:co-surfactant) at the selected ratio.
   • Mix oil phase (with drug) and Smix, then add the aqueous phase dropwise under magnetic stirring to form a coarse emulsion[2][3][4][10].
   • Subject the emulsion to ultrasonication (e.g., 15–20 min) or pass through a high-pressure homogenizer (e.g., 3–5 cycles, 10,000–20,000 psi) to obtain nanoemulsion[2][3][4][8].
   • Adjust pH as necessary.

4. Characterization:

   • Particle Size & PDI: Measure using DLS; expect a mean particle size <200 nm and PDI <0.3 for uniform distribution[2][3][4][6][7][8][10].
   • Zeta Potential: Assess surface charge for colloidal stability, ideally |ζ| > 20 mV.
   • Physical Stability: Subject to centrifugation (e.g., 3000 rpm, 30 min), freeze-thaw cycles, and storage at 4°C, 25°C, and 40°C for 1, 7, 30, 90 days. Monitor for phase separation, creaming, cracking, and turbidity[3][6][7][10].
   • Drug Content: Analyze aliquots for drug content using validated UV spectrophotometric or HPLC method[8].
   • pH & Viscosity: Record using standard meters/instruments.
   • In Vitro Drug Release: Use dialysis bag or Franz diffusion cell. Place defined amount of nanoemulsion in donor compartment, receptor filled with buffer (e.g., PBS), and sample aliquots withdrawn at intervals for drug quantification and cumulative release (%) vs. time profile[2][3][4][7][8][10].
   • Morphology: Optionally, assess vesicle shape and surface by transmission electron microscopy or similar imaging[2].

Storage

• Store nanoemulsion in amber glass vials at 4–8°C and ambient temperature to evaluate stability under stress and real-time conditions. Protect from light and microbial contamination[3][6][8][10].

Formulation Table (For 10 mL batch; example with celecoxib[5][6])

*Drug amount adjusted based on maximum solubility in the oil and Smix.

For other drugs, adjust the oil, surfactant, and co-surfactant system as per drug solubility screening[2][3][4][7][8].

Label Example

For Laboratory Research Use
Nanoemulsion – [Drug Name]
Batch No.: NE-[XXX]
Date of Preparation: [DD/MM/YYYY]
Store at 4–8 °C, protected from light
For experimental use, not for administration
Prepared by: [Name]
Supervisor: [Name]

Report: Recommended Format

• Title: Formulation and Characterization of [Drug Name] Nanoemulsion for Enhanced Delivery
• Abstract: Brief summary of aim, method, results (mean droplet size, PDI, stability, % drug release), and conclusions.
• Introduction: Overview of nanoemulsion relevance in drug delivery (enhanced solubility, stability, bioavailability); justification for drug selection[1][2][3][4][5][6][7][8][9][10].
• Materials and Methods:
  • Materials: List with sources and purities
  • Formulation: All steps from screening to nanoemulsion preparation
  • Characterization: Analytical techniques used
• Results:
  • Mean particle size, PDI, zeta potential (tabulated/graphical)
  • Drug content (%)
  • pH, viscosity
  • In vitro release plot (% cumulative release vs. time)
  • Stability findings: observations at various temperatures/times
• Discussion:
  • Impact of composition and process on size, PDI, stability
  • Comparison against literature and conventional formulations (bioavailability, release kinetics)[2][3][10].
  • Correlation between formulation variables and performance
• Conclusion: Summary of key findings and their implication for drug delivery
• **References: